Now Available: CTTI Symposium Presentations

For those unable to attend the CTTI 10-year Symposium on Feb. 6, we are pleased to share slides from each of the exciting, informative sessions:

Meeting Presentations

  1. Welcome and Introduction to CTTI by Pamela Tenaerts, CTTI
  2. Welcome from the Executive Committee by Jacqueline Corrigan-Curay, FDA, CDER
  3. Keynote Address by Robert Califf, Duke University / Verily
  4. Reflection on Quality by Design by Robert Temple, FDA, CDER
  5. Quality by Design Project Overview and Recommendations by Ann Meeker-O’Connell, Johnson & Johnson
  6. Quality by Design Case Study by Julie Dietrich, Amgen, Inc
  7. PGCT Project Overview and Recommendations by Bray Patrick-Lake, Duke Clinical Research Institute
  8. PGCT Case Study by Ron Bartek, Friedreich’s Ataxia Research Alliance
  9. PGCT Case Study by Jeff Sherman, Horizon Pharma
  10. Single IRB of Record Project Overview and Recommendations by Soo Bang, Celegene
  11. Single IRB of Record Case Study by Hallie Kassan, Feinstein Institute for Medical Research, Northwell Health

Thank you again to all of our esteemed presenters who made the CTTI Symposium a great success! Keep an eye on this blog for a complete recap of the event later this week.

CTTI Publishes Recommendations to Enhance Data Monitoring Committees

Improve trial oversight by applying best practices for DMC setup and operation

CTTI has published recommendations to enhance the functioning of data monitoring committees (DMCs) for clinical trials. Sponsors, DMC members, and all those involved in clinical trial design and conduct can apply CTTI’s recommendations to improve DMC operation and the quality of trial oversight, which ultimately benefits patients.

The monitoring of accumulating data in a clinical trial helps to ensure participant safety, as well as the validity and integrity of the trial. For an increasing number of trials, this is accomplished through an independent DMC that can advise on whether to continue, modify, or terminate a trial based on a benefit-risk assessment. Though DMCs play an important role in the oversight of clinical trials, there is considerable variability in how they are composed and operate.

CTTI’s recommendations, which appear in the journal Clinical Trials, address the following areas:

  • Clarifying the role of DMCs
  • Best practices for DMC conduct
  • Effective communication practices
  • Strategies for preparing the next generation of DMC members

The recommendations were developed through a consensus of experts from multiple stakeholder groups after collecting and analyzing data on DMC practices.

Learn more about CTTI’s Data Monitoring Committees Project.

CTTI Leads Workshop and Shares Findings at International Meeting on Clinical Trials

LOOK FOR US AT SCT ICTMC 2017 IN LIVERPOOL FOR STRATEGIES TO IMPROVE THE QUALITY AND EFFICIENCY OF CLINICAL TRIALS

You’re headed to Liverpool, take this printable one page schedule of CTTI’s presentations at the meeting. See you there!

CTTI will present its recommendations and latest findings in five sessions at the International Clinical Trials Methodology Conference (ICTMC) and Society for Clinical Trials (SCT) Annual Meeting, May 7-10, 2017. We will lead a hands-on workshop on best practices for Data Monitoring Committees, and share our evidence and strategies on embedding randomized clinical trials within registries, developing novel endpoints generated by mobile technology, and more.


Session Title: Formative Research Findings on the Design of an Early Enrollment Clinical Trial on Hospital Acquired Bacterial Pneumonia (HABP) and Ventilator Associated Bacterial Pneumonia (VABP) (Parallel Session 1.5 – Qualitative Research)
Date & Time: Monday May 8 from 1:30–2:30 p.m.
Speaker: Amy Corneli, Duke University
Related CTTI Project: HABP/VABP Studies


Post/our-work/novel-clinical-trial-designs/antibiotic-drug-development/abdd-habp-vabp-studies/er Abstract: Embedding Randomized Clinical Trials within Registries: How Feasible? (Poster Board #152)
Date & Time: Monday, May 8 from 3:40–4:25 p.m.
Speaker: Ted Lystig, Medtronic
Related CTTI Project: Registry Trials


Poster Abstract: Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials: A Clinical Trials Transformation Initiative (CTTI) Project (Poster Board #153)
Date & Time: Monday, May 8 from 3:40–4:25 p.m.
Speaker: Martin Landray, University of Oxford
Related CTTI Project: MCT Novel Endpoints


Workshop Title: Data Monitoring Committees: Multi-stakeholder Recommendations and Hands-on Experience from CTTI and the MRCT Center (Workshop 3)
Date & Time: Tuesday, May 9 from 8:30–10:00 a.m.
Speaker: Annemarie Forrest, CTTI
Related CTTI Project: DMCs


Panel: Clinical / Outcomes Registry-Based Randomised Controlled Trials – The Future for Clinical Trials? (Invited Session 3.5)
Date & Time: Tuesday, May 9 from 8:30–10:00 a.m.
Speaker: Ted Lystig, Medtronic
Related CTTI Project: Registry Trials

CTTI Publishes Findings on Stakeholder Perceptions of IND Reporting Process in Oncology Trials

CTTI has published its findings on remaining barriers and potential solutions to full implementation of the FDA final rule on IND safety reporting by investigators, clinical research staff, and sponsors.

In 2010, the FDA final rule established new reporting requirements for serious and unexpected suspected adverse events occurring in clinical trials conducted under an IND. Follow-up FDA guidance clarified sponsors’ role and that they should not submit expedited safety reports for individual cases of serious adverse events for which it does not appear the drug caused the event. It was anticipated that these changes could increase the interpretability of safety reports while decreasing the volume and burden of reporting.

Through a series of surveys and interviews, the results of which were published in the journal Clinical Trials, CTTI discovered that while all groups agreed on the intention of the final rule in increasing early communication of safety signals, they also indicated that the rule was not being strictly implemented. Interviewees reported that the major challenges included lack of global harmonization in reporting rules, difficulties determining causality, and fear of regulatory repercussions, some of which could be improved with increased interaction with the FDA itself.

These findings, which resulted from CTTI’s IND Safety Reporting Project, support recommendations developed by CTTI and underpin educational materials created for sponsors to increase compliance with the final rule, and to facilitate discussion between sponsors, investigators, and FDA representatives. CTTI gathered input on these findings and their impact in a multi-stakeholder expert meeting (a meeting summary is available for additional context) and hosted a webinar to provide guidance on handling a variety of safety reporting situations.

CTTI would like to thank the interview participants and project team members who contributed to this work.

Navigating the Updated Common Rule

CTTI TOOLS AND RECOMMENDATIONS CAN HELP RESEARCHERS MEET NEW REQUIREMENTS FOR INFORMED CONSENT DOCUMENTS AND CENTRAL IRBS

This year the US Department of Health and Human Services released long-awaited updates to the Federal Policy for the Protection of Human Subjects, better known as the Common Rule. Originally issued in 1991, the Common Rule governs a large proportion of U.S. research involving human participants. CTTI offers resources and tools that can help investigators seeking to understand and implement some of these new requirements, including recommendations that closely parallel key Common Rule standards for informed consent documents and the use of central institutional review boards (central IRBs).

Informed Consent Documents

The revised Common Rule states that informed consent documents (ICDs) “…must begin with a concise and focused presentation of the key information” that is most likely to help prospective study participants understand the reasons for or against participating in a trial.  CTTI’s recommendations for using shorter, simpler informed consent documents that utilize a “tiered approach” to presenting information and incorporate health literacy and reading level assessments provide a structured path that can help in creating ICDs that satisfy Common Rule requirements:

SIMILARITIES BETWEEN COMMON RULE REQUIREMENTS & CTTI RECOMMENDATIONS FOR INFORMED CONSENT DOCUMENTS

New Common Rule Requirements for Informed Consent Documents (2017)CTTI Recommendations for Informed Consent Documents (2013)Concise and focused presentation of key information most likely to assist a prospective subject or legally authorized representative in understanding the reasons why one might or might not want to participate in the research.

Information in this part of the ICD must be organized and presented in a way that facilitates comprehension. Use of tiered approach, including:

  • Section that includes only elements required by federal regulations
  • Additional information in chapter format
  • 1-2 page summary of the study

Draft ICDs should be evaluated with:

  • Standardized health literacy/plain language assessments
  • Reading level assessments
  • Usability testing with comparable patients

Source: Federal Policy for the Protection of Human Subjects https://www.federalregister.gov/documents/2017/01/19/2017-01058/federal-policy-for-the-protection-of-human-subjects Source: CTTI Recommendations: https://ctti-clinicaltrials.org/files/ctti-informedconsent-recs.pdf

Use of a Single or Central IRB

Another facet of the revised Common Rule that harmonizes with CTTI recommendations relates to the use of single IRBs for oversight of research activities in multicenter trials. In 2013, CTTI recommended the use of a central IRB (in other words, a single IRB of record for all research sites participating in a clinical study) in order to improve quality and efficiency. Although the Common Rule does not require all multisite trials to use a central IRB, it does mandate that U.S. institutions involved in cooperative research in the United States (with certain exceptions) use a single IRB and notes that

When working optimally, we expect the central IRB model will work more efficiently and require less personnel time and fewer resources for tracking and implementing IRB changes and approvals, thereby eliminating the potential for unnecessarily duplicative reviews.

CTTI offers several tools that can assist research sites, sponsors, and IRBs in successfully navigating the challenges of using a central IRB model, including a template IRB authorization agreement; an evaluation checklist that helps sites assess readiness, helps sites or sponsors select a central IRB, and helps central IRBs to assess research sites; and a considerations document that delineates the central IRB’s responsibilities versus the site’s institutional obligations.

 

For complete listings of publicly available CTTI implementation tools and recommendations, visit the CTTI website.

Improve Electronic Portals for IND Safety Reporting With CTTI’s Recommendations

CTTI’s latest research indicates that a single, internet-based portal for investigator reporting of expedited IND safety information to sponsors would be better than the current system of each sponsor having a separate portal. However, until use of a central portal is feasible, the recently published findings and CTTI recommendations provide desired attributes that can promote consistent functionality across electronic portals, improving the quality and use of these systems.

Electronic portals can increase efficiency and lower costs associated with processing safety reports in clinical trials, as well as add an element of security. However, there can be challenges associated with use of these systems that prevent successful adoption. CTTI’s IND Safety Advancement Project sought to identify obstacles and to create recommendations for best practices for following FDA requirements and guidance on expedited safety reporting. Electronic portals are one method sites and sponsors can implement to help adhere to FDA requirements and improve the quality of safety reports.

The recommendations for electronic portals for IND safety reporting are based on results from interviews with research staff, along with multi-stakeholder input on how to address the challenges raised. For example, CTTI found that many research staff report difficulties in tracking multiple passwords and managing different interfaces for various sponsor portals. These research staff views helped to inform strategies that could decrease the burden of IND safety reporting in clinical trials.

For those in the clinical trials enterprise seeking to streamline IND safety reporting, additional recommendations are available from CTTI to improve IND safety assessment and communication.

Happy Holidays from CTTI – Gifts you can use

Happy Holidays

If quality, efficient trials are on your wish list, we’ve got you covered.

CTTI’s latest recommendations and tools:

In 2016, there were over 30,000 downloads from the CTTI website. Popular favorites include our evidence-based recommendations on trial qualityinformed consent, and patient group engagement.

By engaging all stakeholders to develop actionable solutions, we are creating a better system for clinical trials. Thank you to all of our members and contributors for their efforts this past year, and best wishes for a successful 2017!